Prognosis
Pfizer, BioNTech in EU Vaccine Deal That’s Their Biggest Yet
- Deal includes initial 200 million doses, 100 million options
- EU, companies in contract talks after preliminary accord
A pedestrian wearing a protective mask passing in front of Pfizer Inc. signage is reflected outside the company's headquarters in New York.
Photographer: Jeenah Moon/BloombergThis article is for subscribers only.
Pfizer Inc. and BioNTech SE reached a preliminary agreement to supply 200 million doses of their experimental Covid-19 vaccine to the European Union -- the biggest initial order yet for the U.S.-German partners.
The European Commission has concluded exploratory talks and will now begin contract negotiations, according to a statement Wednesday. The deal would include an option for another 100 million doses.